Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy, Biologic therapy.

St. Bartholomew's Hospital, London, United Kingdom.

Survival: monthsCountry:United Kingdom
Toxiciy Grade:4City/State/Province:London
Treatments:Chemotherapy, Biologic therapyHospital:St. Bartholomew's Hospital
Drugs:Journal:Link
Date:Feb 2008

Description:

Patients: This phase II study involved 24 patients with advanced, metastatic colorectal cancer. These patients had been treated with capecitabine or 5-fluoruracil (5-FU) previously. There were 14 men and 10 women; the average age was 64.3, ranging from 39-83 years of age.

Treatment: Patients were treated with the biological therapy gefitinib and the chemotherapy 5-FU.

Toxicity: Grade 3/4 dehydration, malaise, stomatitis and nausea were reported. Grade 1 or 2 toxicities included rash, diarrhea, erythema, alopecia, and fatigue.

Results: The median overall survival was 7.4 months (226 days).

Support: This study was supported by AstraZeneca, which markets gefitinib as Iressa“.

Correspondence: Dr. D. Propper



Back